Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma

Phase

N/A

Condition

Asthma

Treatment

Blood sample

Nasopharyngeal swab

Expectoration

Clinical Study ID

NCT06044051

2023/0091/HP

Ages < 24
All Genders

Study Summary

Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment.

Exploring and understanding these data is to improve patient care and discover new therapeutic targets.

The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Infants less than 24 months old
Follow-up by a pneumo-pediatrician for severe asthma in infants
Requiring etiological investigations and assessment of severity in dayhospitalization, including bronchial fibroscopy (HAS 2009)
Parent informed of the research and having signed consent

Exclusion

Exclusion Criteria:

Prematurity <32 WA
Congenital heart disease with significant left to right shunt
Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitisobliterans)
Antibiotic therapy in progress or administered the seven days preceding the date ofinclusion (day hospitalization)
Refusal of bronchial fibroscopy

Study Design